For the second time in two years, Radius Health is taking itself out of the IPO queue. The Cambridge, MA-based company has postponed its IPO, citing “poor market conditions,” according to IPO research firm Renaissance Capital. Radius had been looking to raise about $75 million and list on the Nasdaq under the ticker symbol “RDUS.” The biotech IPO market was sizzling hot in 2013 and remained that way only months ago. In January, Dicerna Pharmaceuticals (NASDAQ: DRNA) priced ahead of its range and immediately tripled in value, symbolizing the fervor for biotech.